Literature DB >> 33488890

Power Calculations for Two-Wave, Change from Baseline to Follow-up Study Designs.

M Colin Ard1, Steven D Edland1,2.   

Abstract

Change in a quantitative trait is commonly employed as an endpoint in two-wave longitudinal studies. For example, early phase clinical trials often use two-wave designs with biomarker endpoints to confirm that a treatment affects the putative target treatment pathway before proceeding to larger scale clinical efficacy trials. Power calculations for such designs are straightforward if pilot data from longitudinal investigations of similar duration to the proposed study are available. Often longitudinal pilot data of similar duration are not available, and simplifying assumptions are used to calculate sample size from cross-sectional data, one standard approach being to use a formula based on variance estimated from cross sectional data and correlation estimates abstracted from the literature or inferred from experience with similar endpoints. An implicit assumption of this standard approach is that the variance of the quantitative trait is the same at baseline and follow-up. In practice, this assumption rarely holds, and sample size estimates by this standard formula can be dramatically anti-conservative. Even when longitudinal pilot data for estimating parameters required in sample size calculations are available, sample size calculations will be biased if the interval from baseline to follow-up is not of similar duration to that proposed for the study being designed. In this paper we characterize the magnitude of bias in sample size estimates when formula assumptions do not hold and derive alternative conservative formulas for sample size required to achieve nominal power.

Entities:  

Keywords:  Clinical Trial; Compound Symmetry; Phase 2; Phase II; Rate of Change; Sample Size

Year:  2012        PMID: 33488890      PMCID: PMC7822571          DOI: 10.6000/1929-6029.2012.01.01.03

Source DB:  PubMed          Journal:  Int J Stat Med Res        ISSN: 1929-6029


  12 in total

Review 1.  The role of biomarkers in clinical trials for Alzheimer disease.

Authors:  Leon J Thal; Kejal Kantarci; Eric M Reiman; William E Klunk; Michael W Weiner; Henrik Zetterberg; Douglas Galasko; Domenico Praticò; Sue Griffin; Dale Schenk; Eric Siemers
Journal:  Alzheimer Dis Assoc Disord       Date:  2006 Jan-Mar       Impact factor: 2.703

2.  Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study.

Authors:  R C Mohs; D Knopman; R C Petersen; S H Ferris; C Ernesto; M Grundman; M Sano; L Bieliauskas; D Geldmacher; C Clark; L J Thal
Journal:  Alzheimer Dis Assoc Disord       Date:  1997       Impact factor: 2.703

3.  Sample size estimation for randomized pre-post designs.

Authors:  J E Overall; R R Starbuck
Journal:  J Psychiatr Res       Date:  1979       Impact factor: 4.791

4.  Neuroimaging enrichment strategy for secondary prevention trials in Alzheimer disease.

Authors:  Linda K McEvoy; Steven D Edland; Dominic Holland; Donald J Hagler; J Cooper Roddey; Christine Fennema-Notestine; David P Salmon; Alain K Koyama; Paul S Aisen; James B Brewer; Anders M Dale
Journal:  Alzheimer Dis Assoc Disord       Date:  2010 Jul-Sep       Impact factor: 2.703

5.  Estimating sample sizes for repeated measurement designs.

Authors:  J E Overall; S R Doyle
Journal:  Control Clin Trials       Date:  1994-04

6.  Introduction to sample size determination and power analysis for clinical trials.

Authors:  J M Lachin
Journal:  Control Clin Trials       Date:  1981-06

Review 7.  Power calculations for clinical trials in Alzheimer's disease.

Authors:  M Colin Ard; Steven D Edland
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

Review 8.  Imaging-based measures of disease progression in clinical trials of disease-modifying drugs for Alzheimer disease.

Authors:  Brandy Matthews; Eric R Siemers; P David Mozley
Journal:  Am J Geriatr Psychiatry       Date:  2003 Mar-Apr       Impact factor: 4.105

9.  Optimal design of clinical trials for drugs designed to slow the course of Alzheimer's disease.

Authors:  Richard C Mohs; Claudia Kawas; Maria C Carrillo
Journal:  Alzheimers Dement       Date:  2006-07       Impact factor: 21.566

Review 10.  Core biological marker candidates of Alzheimer's disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity.

Authors:  H Hampel; A Mitchell; K Blennow; R A Frank; S Brettschneider; L Weller; H-J Möller
Journal:  J Neural Transm (Vienna)       Date:  2003-12-03       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.